Kridin K, Brüggen MC, Chua SL, et al. - Findings not only indicate differences in treatment approaches for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Europe but also emphasize the importance of prospective therapeutic studies and registries.

• A retrospective pan-European multicenter cohort study of 212 patients with SJS/TEN to explore treatment approaches across Europe and results related to the SJS/TEN disease course, as well as risk factors and culprit drugs.

• Treatment approaches used to treat SJS/TEN ranged from best supportive care only (38.2%) to systemic glucocorticoids (35.4%), intravenous immunoglobulins (23.6%), cyclosporine (10.4%), and antitumor necrosis factor agents (3.3%).

• Severe acute-phase complications occurred in most cases (63.7%), and the 6-week mortality rate was 20.8%.

• A culprit drug was found in 176 (83.0%) cases; the most common suspected agents included antibiotics (21.2%), followed by anticonvulsants (18.9%), nonsteroidal anti-inflammatory drugs (11.8%), allopurinol (11.3%), and sulfonamides (10.4%).

• A decreased risk of infections (adjusted OR, 0.40) was noted with systemic glucocorticoids and intravenous immunoglobulins, whereas an increased risk of infections (adjusted OR, 7.16) was observed with cyclosporine.